9-(hydroxyethoxymethyl)-2-N-(9-phenylxanthen-9-yl)-guanine | 96802-10-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 9-(hydroxyethoxymethyl)-2-N-(9-phenylxanthen-9-yl)-guanine
• 英文别名: 9-(2-hydroxyethoxymethyl)-2-[(9-phenylxanthen-9-yl)amino]-1H-purin-6-one
• CAS: 96802-10-7
• 化学式: C₂₇H₂₃N₅O₄
• 分子量: 481.511
• InChiKey: HTPLXTZVTULCMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  9-(hydroxyethoxymethyl)-2-N-(9-phenylxanthen-9-yl)-guanine 在 对甲苯磺酸一水合物 、 四丁基氟化铵 、 苯甲基-2-磺酰三硝基三氮唑 作用下， 以 吡啶 为溶剂， 生成 Tetradecanoic acid 2-{[2-(2-amino-6-oxo-1,6-dihydro-purin-9-ylmethoxy)-ethoxy]-hydroxy-phosphoryloxy}-1-tetradecanoyloxymethyl-ethyl ester; compound with triethyl-amine
  参考文献：
  名称：

  The Chemical Synthesis and Antiviral Properties of an Acyclovir-phospholipid Conjugate.

  摘要：

  The synthesis of acyclovir-phospholipid conjugate (2) is reported through an unambiguous one-step preparation of L-alpha-dimyristoyl phosphatidic acid triethylammonium salt (5). The biological activity of 2 as an antiviral drug has also been investigated.

  DOI：

  10.3891/acta.chem.scand.39b-0047
• 作为产物：
  描述：

  阿昔洛韦 、 9-氯-9-苯基氧杂蒽 生成 9-(hydroxyethoxymethyl)-2-N-(9-phenylxanthen-9-yl)-guanine
  参考文献：
  名称：

  The Chemical Synthesis and Antiviral Properties of an Acyclovir-phospholipid Conjugate.

  摘要：

  The synthesis of acyclovir-phospholipid conjugate (2) is reported through an unambiguous one-step preparation of L-alpha-dimyristoyl phosphatidic acid triethylammonium salt (5). The biological activity of 2 as an antiviral drug has also been investigated.

  DOI：

  10.3891/acta.chem.scand.39b-0047

文献信息

• US5789589A
  申请人：——

  公开号：US5789589A

  公开（公告）日：1998-08-04
• [EN] PRODRUGS OF ACYCLOVIR<br/>[FR] PROMEDICAMENTS D'ACYCLOVIR
  申请人：DRUG INNOVATION & DESIGN, INC.

  公开号：WO1997040056A1

  公开（公告）日：1997-10-30

  (EN) Disclosed are novel prodrugs represented by structural formulas (I) or (II). Z is oxygen or sulfur; n is 1 or 2; Y is, together with a hydroxy group, acyclovir or an analog of acyclovir; A is a group which can be metabolized $i(in vivo) to give a modified A such that the phosphoester bond (modified A) - O undergoes cleavage $i(in vivo). Also disclosed is a method of treating a viral infection in an individual or animal. The method comprises administering to the individual or animal a therapeutically effective amount of a prodrug represented by structural formulas shown above.(FR) Cette invention se rapporte à de nouveaux promédicaments représentés par les formules structurales (I) et (II) dans lesquelles Z est oxygène ou soufre, n est égal à 1 ou 2, Y est, en association avec un groupe hydroxy, acyclovir ou analogue d'acyclovir, A est un groupe qui peut être métabolisé $i(in vivo) de façon à former un A modifié qui est tel que la liaison phosphoester (A modifié)_ O subit une scission $i(in vivo). L'invention se rapporte également à un procédé de traitement d'une infection virale chez un individu ou un animal. Ledit procédé consiste à administrer audit individu ou animal une quantité thérapeutiquement efficace d'un promédicament représenté par les formules présentées ci-dessus.
• The Chemical Synthesis and Antiviral Properties of an Acyclovir-phospholipid Conjugate.
  作者：C. J. Welch、A. Larsson、A. C. Ericson、B. Öberg、R. Datema、J. Chattopadhyaya

  DOI：10.3891/acta.chem.scand.39b-0047

  日期：——

  The synthesis of acyclovir-phospholipid conjugate (2) is reported through an unambiguous one-step preparation of L-alpha-dimyristoyl phosphatidic acid triethylammonium salt (5). The biological activity of 2 as an antiviral drug has also been investigated.